On the other hand, activation of receptors belonging to the D 2 -like family (D 2 , D 3 , and D 4 ) leads to the inhibition of protein G and adenylate cyclase and triggers sodium channels.
neurohormonal balance, as it is in the case of dopamine. 4 Intravenous administration of dopamine in patients with multiorgan injuries resulted in decreased thyroid-stimulating hormone (TSH), triiodothyronine (T 3 ), and thyroxine (T 4 ) release, while discontinution of the infusion led to a 3-fold increase in TSH levels as well as increase of serum T 3 . These fluctuations were usually disappearing after 24 hours post infusion. 15 Inhibition of several other hormones was reported following intravenous dopamine infusion, including growth hormone (GH), prolactin (PRL), and luteinizing hormone. [15] [16] [17] [18] Dopamine infusions administered in low birth weight infants caused transient reduction of T 4 , TSH, and PRL levels with a subsequent increase after discontinuing the treatment, while GH levels remained unchanged. 19 Our current study assesses the effect of intravenous dopamine infusion on pituitary function including changes in serum TSH and ACTH levels, thyroid function, and potential nephroprotective effect in patients with acute heart failure PAtIents And methods The study involved 29 patients of the cardiology department admitted in 2009-2010 with acute heart failure diagnosed as chronic decompensated heart failure (New York Heart Association class III/IV; mean age 77.4 ±13.3 years). There were 17 women (mean age 81.9 ±8.6 years) and 12 men (mean age 71.1 ±14.4 years). Diagnosis of chronic heart failure was established at least 6 months prior to the admission. Characteristics of the study population are presented in tAble 1.
Patients with stage 4/5 kidney damage, liver failure, thyroid disease, neoplastic disease, acute inflammatory disorders, individuals undergoing immunosuppressive or glucocorticoid therapy, as well as those with glycemia above 400 mg/dl (22.2 mmol/l) were excluded from the study.
Intravenous dopamine infusion was administered in doses varying from 1 to 5 μg/kg/min. Blood pressure was carefully monitored during the procedure, as recommended in the guidelines of the European Society of Cardiology and the Polish Cardiac Society on the management of chronic decompensated heart failure. Dopamine was administered only in patients who failed to respond to previous optimized pharmaco logical treatment and continued to display the symptoms of decompensated chronic heart failure. Patients who required increase in dopamine dose above the initially established limit were excluded from the study. Each infusion lasted 72 hours. The measurement of TSH, free triiodothyronine (FT 3 ), free thyroxine (FT 4 ), and ACTH levels was taken directly before the infusion (timepoint 0), at 12 hours (timepoint 1), and 12 hours after the infusion was completed (timepoint 2).
Laboratory measurements were performed using the Wizard2470 auto matic gamma counter. The serum levels of FT 3 and FT 4 were measured using radioimmunoassay kits RIAZENcoFT 3 and RIAZENcoFT 4 , respectively (ZenTEch, Angleur, Begium). The normal values were 3.4-7.2 pmol/l for FT 3 and 10.3-25.7 pmol/l for FT 4 . The serum nevertheless, some regions within the hypothalamus and pituitary gland lack such a barrier, allowing for the exchange of active components to occur and exogenous dopamine to enter the CNS and modulate its function. 4, 5 Acting in the periphery, dopamine can either inhibit (via D2-like receptor family) or stimulate (via D1-like receptor family) the release of catecholamines. Interestingly, low doses of dopamine downregulate, while high doses stimulate, the release of norepinephrine.
6,7
Dopamine receptors are also present in the kidneys. It was shown that intravenous infusion of dopamine increases glomerular filtration, diuresis, and natriuresis. 8 The mechanism underlying the increase in diuresis and natriuresis has not yet been elucidated and several theories have been put forward, including the increase in cardiac output due to the stimulation of β 1 receptors, D1-and α receptor-mediated increase in renal flow and perfusion, and finally, downregulation of the release of aldosterone and inhibition of sodium-potassium adenosinotriphosphatase in renal tubular epithelium.
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In current medical practice, dopamine treatment is commonly used as a mean to achieve nephroprotection. Nevertheless, it has to be emphasized that very few studies unequivocally supported the use of dopamine as a beneficial treatment in acute renal failure.
10 Moreover, treatment with dopamine may lead to severe adverse effects such as cardiac ischemia, arrhythmia, hypoventilation, increase in pulmonary shunt, and disturbance of gastrointestinal motility and blood flow.
11 Indeed, the majority of reports involving patients with sepsis or early renal dysfunction failed to confirm the postulated nephroprotective action of dopamine.
12-14
Dysfunction of hypothalamus-pituitary-thyroid axis, commonly occurring in critically ill patients, may be further amplified by drugs affecting where: eGFR -estimated GFR (ml/min/1.73 m 2 ).
Our study was performed in agreement with the guidelines of the Helsinki Declaration and was approved by the local ethics committee.
statistical analysis The results obtained in our study were subsequently analyzed statistically. First, repeated measures analysis of variance (ANOVA) test with 3 measurements for each variable was performed. Next, the post hoc Turkey test for the group of variables with statistical differences was performed in order to establish the statistical significance of the differences. Additionally, changes in pulse rate and blood pressure measured prior to and after 12 hours of dopamine infusion and GFR values measured at timepoints 0, 1, and 2 were analyzed using repeated measures ANOVA test. Finally, the Pearson's correlation coefficient (r) was calculated, with the level of statistical significance of P <0.05.
results The ejection fraction (EF) was assessed by echocardiography and was 40.0% ±15.4%. In 65% of the patients, ischemia was the underlying cause of heart failure; valvular heart disease and other cardiovascular diseases were also observed (independently or coexistent with ischemia; tAble 1).
The results are summarized in tAbles 2-5 and Serum FT 3 levels 12 hours after dopamine infusion were significantly lower than before the infusion (P <0.005). Serum FT 4 levels at 12 hours of continuous infusion as well as 12 hours after the infusion were significantly lower than before the infusion (P <0.05 and P <0.005, respectively).
There was no statistically significant difference between consecutive measurements of serum TSH and ACTH during and after the infusion. At timepoint 1 (12 hours into the infusion procedure), a borderline correlation between the levels levels of TSH were measured using the radioimmunoassay kit (DIAsource ImmunoAssays S.A., Belgium). The normal values for TSH were 0.2-3.2 μIU/ml. The serum levels of human adrenocorticotropic hormone (ACTH) were measured in EDTA plasma using the radioimmunoassay kit (DIAsource ImmunoAssays S.A.). The normal values were 9.6-49.7 pg/ml.
The glomerular filtration rate (GFR) was calculated according to the Modification of Diet in Renal Disease formula (MDRD): Abbreviations: DBP -diastolic blood pressure, SBP -systolic blood pressure, GFRglomerular filtration rate, PR -pulse rate, others -see tAble 2 of the anterior pituitary seems to depend on the administered dose. We did not observe a significant effect of small doses of dopamine on serum TSH and ACTH levels. Nevertheless, thyroid function was significantly suppressed as suggested by the decreased levels of serum FT 3 and FT 4 after dopamine infusion. While analyzing our data from the "cause-effect" point of view, it is important to mention the previously published studies reporting a decrease of thyroid hormone levels in severely ill patients regardless of a treatment modality. Euthyroid sick syndrome diagnosed in these patients is characterized by low levels of FT 3 and FT 4 due to various extrathyroidal factors, such as systemic diseases, surgery or injuries, rather than to thyroid dysfunction. 20, 21 On the other hand, the pituitary circadian rhythmic release of ACTH is stimulated by hypothalamus-derived corticoliberin. The highest ACTH levels are typically released in the morning and decrease continuously throughout the day to reach the lowest values in the evening. Several stress factors such as pain, hypoxia, hypoglycemia, surgery, etc., may deregulate this pattern of release. 22 It was shown that disturbance in circadian activation of the hypothalamus-pituitary axis in critically ill patients was related to the severity of the disease. 23 Importantly, such disturbances may be additionally enhanced iatrogenically, e.g., by administration of dopamine.
4
The decision to administer dopamine is often supported by the need for so called nephroprotection, which allows to preserve diuretic and endocrine kidney function, but most importantly, to maintain efficient plasma filtration rate as measured by creatinine clearance. The mechanisms that promote a dopamine-dependent increase in diuresis and natriuresis have not yet been fully characterized. Moreover, the majority of reports published up to date have not confirmed the potentially beneficial effect of dopamine infusion on kidney function. The administration of 3 μg/kg/min for 2 hours in sepsis patients without concomitant oliguria resulted in increased diuresis but had no effect on creatinine clearance and did not lead to nephroprotection.
12 Combination therapy of 1 μg/kg/min of dopamine and furosemide proved to be beneficial compared with of TSH and ACTH was demonstrated (r = 0.563, P = 0.56).
While the GFR calculated using the MDRD formula increased from 40.86 ml/min at timepoint 0 to 50.24 ml/min at timepoint 2, the observed increase was not statistically significant.
When pulse rate and systolic and diastolic blood pressure were analyzed at various timepoints, no statistically significant differences were noted.
dIscussIon Episodes of decompensation affecting the study population were caused by various pathophysio logical mechanisms, making it particularly difficult to identify and characterize a single factor responsible for their occurrence. Additionally, such multifactorial etiology complicates the process of assessing a possible effect of dopamine on the function of hypothalamus-pituitary-thyroid axis in critically ill patients. According to our findings, the effect of dopamine infusion on neurohormonal function care therapy included the administration of diuretic doses of dopamine. Moreover, such treatment has also been long employed in the United States in patients with end-stage heart failure. Certainly, this debate is far from over, and our report provides further data that may prove valuable in the ongoing discussion. Due to the lack of support for dopamine as an agent able to provide isolated nephroprotection independently without concurrent circulatory improvement, its administration should be limited to patients with a specific hemo dynamic profile. 24, 25 Arbitrary use of diuretic doses of dopamine should be discouraged, while its administration as a vasopressor should require careful consideration and individual assessment of each particular case. 26 The main limitation of our study is a small sample size, which is a common drawback of the studies conducted in intensive care unit patients. It stems from a dilemma of whether to select large groups of patients that are quite heterogeneous in terms of diagnoses and treatment modalities, or much smaller, but relatively homo genous. Our study would also further benefit from analyzing the serum levels of B-type natriuretic peptide (BNP)/N-terminal pro BNP.
Intravenous dopamine infusion has a potential to decrease thyroid function; however, it does not inhibit pituitary release of TSH and ACTH. The current study fails to support the concept that low dose dopamine infusion can improve kidney function in patients with chronic decompensated chronic heart failure. furosemide alone in patients with acute renal failure in the course of malaria, but only when serum creatinine levels were below 4.5 mg%. 10 A significant increase in the GFR was only observed when the dopamine dose reached 7 μg/kg/min. Renal function represented by creatinine clearance was proportionally related to the mean arterial blood pressure. 10 Bellomo et al. 13 reported no statistically significant differences in the creatinine level, hospitalization time, as well as in the frequency of subsequent kidney replacement therapies and deaths between dopamine-and placebo-treated patients with early renal dysfunction. Therefore, the authors concluded that infusion of small doses of dopamine does not improve prognosis in these patients.
In our study, we did not observe significant changes in the GFR nor systemic blood pressure during intravenous dopamine infusion. We can therefore agree with other investigators that dopamine is not nephroprotective.
14 This issue is currently extensively investigated, and was recently discussed during the 2011 Conference of the European Society of Cardiology in Paris, during the session on intensive cardio logic care in patients with advanced heart failure. While Proffesor Kenneth Dickstein (University of Bergen, Norway) suggested that the practice of administering so called diuretic doses of dopamine should possibly be discontinued, Muriel Jessup (University of Pennsylvania, United States) presented a case report of a patient prior to the implantation of ventricular assist device whose intensive FIGure 4 Mean values of serum adrenocorticotropic hormone (ACTH); for timepoints see tAble 2 
